Universe Pharmaceuticals : Results of the Universe Pharmaceuticals INC 2022 Annual General Meeting - Form 6-K
September 28, 2022 at 07:56 pm
Share
Results of the Universe Pharmaceuticals INC 2022 Annual General Meeting
At the 2022 annual general meeting of shareholders (the "Meeting") of Universe Pharmaceuticals INC (the "Company") held at 10:00 a.m. Beijing Time on September 23, 2022, the shareholders of the Company adopted resolutions approving all of the ten proposals considered at the Meeting. A total of 13,407,407 votes, representing 61.64% of the votes exercisable as of August 11, 2022, the record date, were present in person or by proxy at the Meeting. The results of the votes were as follows:
1.
As an ordinary resolution, that Gang Lai be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal One")
Resolution
For
Against
Abstain
Proposal One
12,731,498
281,417
700
Percentage of Voted Shares:
97.83
%
2.16
%
2.
As an ordinary resolution, that Lin Yang be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Two")
Resolution
For
Against
Abstain
Proposal Two
12,480,000
282,754
700
Percentage of Voted Shares:
97.78
%
2.22
%
3.
As an ordinary resolution, that Jiawen Pang be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Three")
Resolution
For
Against
Abstain
Proposal Three
12,371,498
282,404
700
Percentage of Voted Shares:
97.83
%
2.17
%
4.
As an ordinary resolution, that H. David Sherman be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Four")
Resolution
For
Against
Abstain
Proposal Four
12,982,659
281,811
700
Percentage of Voted Shares:
97.88
%
2.12
%
5.
As an ordinary resolution, that Ding Zheng be re-elected as a director of the Company to hold office until the next annual general meeting of the Company ("Proposal Five")
Resolution
For
Against
Abstain
Proposal Five
12,731,161
282,583
700
Percentage of Voted Shares:
97.83
%
2.17
%
6.
As an ordinary resolution, that the Company be authorized to file a shelf registration statement on Form F-3 registering the Company's ordinary shares, preferred shares, debt securities, warrants, rights and units of up to $200 million ("Proposal Six")
Resolution
For
Against
Abstain
Proposal Six
12,731,161
286,760
500
Percentage of Voted Shares:
97.80
%
2.20
%
Attachments
Original Link
Original Document
Permalink
Disclaimer
Universe Pharmaceuticals Inc. published this content on 28 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 September 2022 18:55:05 UTC.
Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.
UNIVERSE PHARMACEUTICALS INC 